Visipaque safer than Hexabrix for angiography:
This article was originally published in Clinica
A large multi-centre US study has shown that Nycomed Amersham's non-ionic contrast agent Visipaque (iodixanol) is safer than its ionic rival, Mallinckrodt's Hexabrix (ioxaglate). In the COURT trial, 856 patients with high-risk cardiac conditions were given angiography with one or other of the agents. The Visipaque group experienced 32% fewer total clinical adverse events and 45% fewer major in-hospital adverse events, according to the study in the May 9 issue of Circulation.
You may also be interested in...
HBW Product Launches: New Chapter Collagen, Alkamind Acid-Kicking, GNC China, Tetra Bio Canada, More
GNC, Harbin launch supplements in China following regulatory approval; Bee Gone expands with allergy swabs; Bed, Bath & Beyond expands distribution of CBDMedic personal care products promoted by Rob Gronkowski; Tetra Bio has Canadian OK For hemorrhoid and pain relief OTCs, US and European pending; Agrozen offers Urban Daze CBD products; New Chapter portfolio expansion also includes fermented vitamins, elderberry supplements and magnesium; and Alkamind’s Acid-Kicking Coffee Alkalizer creamers help neutralize acid from coffee.
In joint complaint, the FTC and New York Attorney General allege scheme to block generic Daraprim and maintain exorbitant list price; they cite hundreds of emails the incarcerated Shkreli has exchanged with co-defendant in last six months.
Biogen value-based contract with UPMC Health Plan ties payments to patient-reported outcomes for Tecfidera and Avonex. The company may seek something similar for Vumerity.